{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T23:19:56Z","timestamp":1787959196672,"version":"build-2784847793"},"reference-count":39,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100020027","name":"Dr Rolf M Schwiete Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100020027","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.bneo.2026.100213","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T17:15:12Z","timestamp":1772471712000},"page":"100213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Targeting the G-protein\u2013coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphoma"],"prefix":"10.1016","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2667-6557","authenticated-orcid":false,"given":"Deniz","family":"\u00d6zistanbullu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9911-1875","authenticated-orcid":false,"given":"Karola","family":"Bahrami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Doll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabi","family":"Reichenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina Sarah","family":"P\u00f6schl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6854-1917","authenticated-orcid":false,"given":"Raphael","family":"Wilhelm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Z\u00f6ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"K\u00f6nig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Spahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven R.","family":"Quist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresia","family":"Scheller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-1189","authenticated-orcid":false,"given":"Lars","family":"Winkler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8859-4103","authenticated-orcid":false,"given":"Bastian","family":"Schilling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Kaufmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Meissner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Kleemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kippenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.bneo.2026.100213_bib1","first-page":"386","article-title":"Mycosis fungoides and S\u00e9zary syndrome - review and outlook","volume":"21","author":"Latzka","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"issue":"S1","key":"10.1016\/j.bneo.2026.100213_bib2","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5045\/br.2023.2023023","article-title":"Mycosis fungoides and S\u00e9zary syndrome","volume":"58","author":"Lee","year":"2023","journal-title":"Blood Res"},{"issue":"8","key":"10.1016\/j.bneo.2026.100213_bib3","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1111\/jdv.19987","article-title":"Classifications of cutaneous lymphomas and lymphoproliferative disorders: an update from the EORTC cutaneous lymphoma histopathology group","volume":"38","author":"Kempf","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100213_bib4","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.bneo.2026.100213_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2026.100213_bib6","doi-asserted-by":"crossref","DOI":"10.2340\/actadv.v102.1087","article-title":"Survival and prognostic factors in patients with aggressive cutaneous T-cell lymphomas","volume":"102","author":"Franceschi","year":"2022","journal-title":"Acta Derm Venereol"},{"issue":"32","key":"10.1016\/j.bneo.2026.100213_bib7","doi-asserted-by":"crossref","first-page":"3766","DOI":"10.1200\/JCO.2015.61.7142","article-title":"Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and S\u00e9zary syndrome: effect of specific prognostic markers on survival and development of a prognostic model","volume":"33","author":"Scarisbrick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100213_bib8","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/ajh.26760","article-title":"Cutaneous T-cell lymphomas: 2023 update on diagnosis, risk-stratification, and management","volume":"98","author":"Hristov","year":"2023","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100213_bib9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1093\/bjd\/ljaf105","article-title":"Therapeutic advances for cutaneous T-cell lymphoma","volume":"193","author":"Bagot","year":"2025","journal-title":"Br J Dermatol"},{"issue":"22","key":"10.1016\/j.bneo.2026.100213_bib10","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1200\/JCO-25-00183","article-title":"Overall survival after allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score-matched controlled prospective study","volume":"43","author":"de Masson","year":"2025","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100213_bib11","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1111\/jdv.19134","article-title":"Effectiveness of mogamulizumab in patients with mycosis fungoides or S\u00e9zary syndrome: a multicentre, retrospective, real-world French study","volume":"37","author":"Beylot-Barry","year":"2023","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100213_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2023.10.001","article-title":"Real-world treatment patterns and clinical outcomes with brentuximab vedotin or other standard therapies in patients with previously treated cutaneous T-cell lymphoma in the United States","volume":"24","author":"Barta","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"21","key":"10.1016\/j.bneo.2026.100213_bib13","doi-asserted-by":"crossref","first-page":"5064","DOI":"10.1182\/blood-2008-10-184168","article-title":"Cutaneous lymphoma incidence patterns in the United States: a population-based study of 3884 cases","volume":"113","author":"Bradford","year":"2009","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.bneo.2026.100213_bib14","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jamaoncol.2022.3236","article-title":"Incidence trends of primary cutaneous T-cell lymphoma in the US From 2000 to 2018: a SEER population data analysis","volume":"8","author":"Cai","year":"2022","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.bneo.2026.100213_bib15","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1016\/j.ejca.2013.04.018","article-title":"A cutaneous lymphoma international prognostic index (CLIPi) for mycosis fungoides and Sezary syndrome","volume":"49","author":"Benton","year":"2013","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100213_bib16","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3109\/10428194.2016.1173210","article-title":"Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and S\u00e9zary syndrome","volume":"57","author":"Danish","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.bneo.2026.100213_bib17","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1002\/path.1883","article-title":"Differential expression of oestrogen receptors in human secondary lymphoid tissues","volume":"208","author":"Shim","year":"2006","journal-title":"J Pathol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100213_bib18","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1038\/leu.2011.68","article-title":"Effect of ligand-activated estrogen receptor \u03b2 on lymphoma growth in vitro and in vivo","volume":"25","author":"Yakimchuk","year":"2011","journal-title":"Leukemia"},{"issue":"1-2","key":"10.1016\/j.bneo.2026.100213_bib19","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.mce.2013.05.016","article-title":"Estrogen receptor \u03b1 and \u03b2 in the normal immune system and in lymphoid malignancies","volume":"375","author":"Yakimchuk","year":"2013","journal-title":"Mol Cell Endocrinol"},{"key":"10.1016\/j.bneo.2026.100213_bib20","article-title":"G protein-coupled estrogen receptor agonist G-1 inhibits mantle cell lymphoma growth in preclinical models","volume":"11","author":"Zhou","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.bneo.2026.100213_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2020.579420","article-title":"G protein-coupled estrogen receptor in immune cells and its role in immune-related diseases","volume":"11","author":"Notas","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.bneo.2026.100213_bib22","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1182\/bloodadvances.2024015132","article-title":"Estrogen receptor \u03b2 stimulation as a possible novel therapeutic target for cutaneous T-cell lymphoma","volume":"9","author":"\u00d6zistanbullu","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"10.1016\/j.bneo.2026.100213_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcmgh.2020.04.016","article-title":"Pharmacologic activation of the G protein-coupled estrogen receptor inhibits pancreatic ductal adenocarcinoma","volume":"10","author":"Natale","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"10.1016\/j.bneo.2026.100213_bib24","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.31770","article-title":"Activation of G protein-coupled estrogen receptor signaling inhibits melanoma and improves response to immune checkpoint blockade","volume":"7","author":"Natale","year":"2018","journal-title":"Elife"},{"issue":"1","key":"10.1016\/j.bneo.2026.100213_bib25","doi-asserted-by":"crossref","DOI":"10.1111\/pcmr.13197","article-title":"An in vivo study of LNS8801, a GPER agonist, in a spontaneous melanoma-prone mouse model, TGS","volume":"38","author":"Marinaro","year":"2025","journal-title":"Pigment Cell Melanoma Res"},{"issue":"4","key":"10.1016\/j.bneo.2026.100213_bib27","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1158\/2767-9764.CRC-24-0632","article-title":"LNS8801: an enantiomerically pure agonist of the G protein-coupled estrogen receptor suitable for clinical development","volume":"5","author":"Natale","year":"2025","journal-title":"Cancer Res Commun"},{"issue":"13","key":"10.1016\/j.bneo.2026.100213_bib29","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/bloodadvances.2025016199","article-title":"LNS-8801 as a therapeutic agent for aggressive lymphomas: ROS-induced cytotoxicity and synergy with existing therapies","volume":"9","author":"Li","year":"2025","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.bneo.2026.100213_bib30","doi-asserted-by":"crossref","first-page":"e458","DOI":"10.3324\/haematol.2015.127399","article-title":"The G protein-coupled estrogen receptor 1 (GPER-1) contributes to the proliferation and survival of mantle cell lymphoma cells","volume":"100","author":"Rudelius","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2026.100213_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.811479","article-title":"The G-protein-coupled estrogen receptor agonist G-1 inhibits proliferation and causes apoptosis in leukemia cell lines of T lineage","volume":"10","author":"Torres-L\u00f3pez","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"10","key":"10.1016\/j.bneo.2026.100213_bib32","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/s41419-022-05357-9","article-title":"Targeted activation of GPER enhances the efficacy of venetoclax by boosting leukemic pyroptosis and CD8+ T cell immune function in acute myeloid leukemia","volume":"13","author":"Ren","year":"2022","journal-title":"Cell Death Dis"},{"issue":"8","key":"10.1016\/j.bneo.2026.100213_bib33","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1158\/2767-9764.CRC-22-0478","article-title":"LNS8801 inhibits acute myeloid leukemia by inducing the production of reactive oxygen species and activating the endoplasmic reticulum stress pathway","volume":"3","author":"Lee","year":"2023","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.bneo.2026.100213_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2024.08.2140","article-title":"1137P Efficacy of LNS8801 in melanoma patients with prior immune-related adverse events from immune-checkpoint inhibitors","volume":"35","author":"Cohen","year":"2024","journal-title":"Annals of Oncology"},{"issue":"16_suppl","key":"10.1016\/j.bneo.2026.100213_bib35","doi-asserted-by":"crossref","first-page":"2574","DOI":"10.1200\/JCO.2022.40.16_suppl.2574","volume":"40","author":"Muller","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.bneo.2026.100213_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2023.09.2235","article-title":"1101P The effect of LNS8801 in combination with pembrolizumab in patients with treatment-refractory cutaneous melanoma","volume":"34","author":"Rodon","year":"2023","journal-title":"Annals of Oncology"},{"issue":"16_suppl","key":"10.1016\/j.bneo.2026.100213_bib37","doi-asserted-by":"crossref","first-page":"9543","DOI":"10.1200\/JCO.2023.41.16_suppl.9543","article-title":"The effect of LNS8801 alone and in combination with pembrolizumab in patients with metastatic uveal melanoma","volume":"41","author":"Shoushtari","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.bneo.2026.100213_bib38","doi-asserted-by":"crossref","DOI":"10.3390\/cells11040593","article-title":"Understanding cell lines, patient-derived xenograft and genetically engineered mouse models used to study cutaneous T-cell lymphoma","volume":"11","author":"Gill","year":"2022","journal-title":"Cells"},{"issue":"12","key":"10.1016\/j.bneo.2026.100213_bib39","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1111\/j.1600-0625.2010.01138.x","article-title":"A novel xenograft model of cutaneous T-cell lymphoma","volume":"19","author":"Krejsgaard","year":"2010","journal-title":"Exp Dermatol"},{"key":"10.1016\/j.bneo.2026.100213_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2024.1372881","article-title":"\u201cNext top\u201d mouse models advancing CTCL research","volume":"12","author":"Luo","year":"2024","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.bneo.2026.100213_bib41","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.0906-6705.2004.00201.x","article-title":"Establishment of a mouse xenograft model for mycosis fungoides","volume":"13","author":"Thaler","year":"2004","journal-title":"Exp Dermatol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T16:27:05Z","timestamp":1779294425000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S2950328026000245"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100213","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the G-protein\u2013coupled estrogen receptor: a novel therapeutic strategy in cutaneous T-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100213","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100213"}}